Get started

Biotechstocks

Familiar T/A on ITRM Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month. "At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug Administration. Currently, the NDA is still under review by the FDA, and the PDUFA goal date is July 25th, 2021. Since the application review for Sulopenem is on track at the moment, ITRM stock is performing well as a result. ITRM stock price has nearly doubled in the last month." Not sure if it gets the approvals necessary but "buy the rumor" might be playing a role here. Quote Source: Top 9 Penny Stocks With High Volume to Watch Right Now
NASDAQ:ITRM
by PennyStocks101
2
Here We Go (Again?) With ATOSThis is familiar territory with ATOS . Not only is there a very clear and significant support level on the chart, there's also a multi-year level of resistance the ATOS is sitting at right now. The biggest question is Now What? " Earlier this month, Atossa revealed data from a Phase 2 Endoxifen study in breast cancer. It met primary and secondary endpoints. The Phase 2 study was conducted on behalf of Atossa by Avance Clinical, a leading Australian CRO. Based on the results, the company also discussed its plan to apply to the FDA for approval to begin a clinical study in the US 'as soon as possible.' With meaningful results and potential for more clinical trials in the US, ATOS could be on the list of biotech penny stocks on Robinhood to watch this summer ." Quote Source: 7 Penny Stocks On Robinhood To Watch In June 2021
NASDAQ:ATOS
by PennyStocks101
13
RGLS Showing Interesting LevelsRGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases. "In mid-May, Regulus Therapeutics announced an incremental update of its autosomal dominant polycystic kidney disease program. The CEO of the company, Jay Hagan said, “As previously reported, the ninth and final patient was trending well at the end of the dosing period and saw their polycystin levels continue to rise until study completion, twenty-eight days after the last dose. This pattern was generally consistent across the first cohort and further enhanced the overall mean changes from baseline for both biomarkers." PLUS upcoming presentation of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021 this Friday (6/25) could be something to keep in mind right now too. Quote Source: 7 Hot Penny Stocks to Watch That Are Trending Right Now
NASDAQ:RGLS
by PennyStocks101
This looks...Familiar on ATOSThis is a very interesting level for ATOS right now. The last two times before this most recent instance the stock failed to break through and hold this level. It was able to do that briefly this year but unsustainable. After consolidating this last time around, what's the catalyst to actually spark a firm move? I think a lot will come down to the next steps for AT-301 to be honest: "Recently ATOS has received phase 2 initiation approval from the Swedish Medical Product Agency for its oral Endoxifen. This drug targets mammographic breast density (MBD), to reduce and eradicate potential tumors. MBD affects millions worldwide and can reduce the effectiveness of mammograms...Doctors around the world depend on mammogram studies to detect cancer through breast density. With a drug such as Endoxifen, it would increase the ability for earlier diagnosis, which in turn could reduce breast cancer incidence... This is a large breakthrough for the company and considering the incidence of breast cancer around the world, Endoxifen could be a big deal moving forward. Investors should stay up to date with any news regarding this compound, as it is Atossa’s flagship product. However, it does have a sizable pipeline that includes a Covid-19 nasal spray treatment known as AT-301." Quote Source: 4 Top Biotech Penny Stocks To Watch In The Second Half Of June 2021
NASDAQ:ATOS
by PennyStocks101
$MBRX Moleculin biotech $MBRX seems to have grit for sellThe Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data far above the expectations of analysts. Recently a reverse split of the stock has also been carried out that reduces the number of titles in circulation. In fact, today the Miracle Viewer indicator that analyzes the graph in search of interests in the market of large players shows an increase in LONG positions by the institutions so you could implement an upward price action. Analyzing the chart, the title seems to have some obstacles along the way but if the interests from the big will remain high will probably be surpassed with limited retracements, according to the signal of Marketmiracle the stock could go even further pushing at the price of 15,50 USD but I would not want in my graphical analysis to exceed the level I indicate as target as it is already a remarkable increment and during the path the title could lose strength. I will try to free cash and enter the stock also because at the moment the balance seems to be shifting a lot on pharmaceuticals and biotech companies so personally I think this is a good opportunity. ( see related other ideas on other biotech and pharma titles ) We will see in the next hours and days if the forecast of Marketmiracle will prove effective. This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:MBRXLong
by MarketMiracleAdvisor
2
Bionano Genomics completes head shoulders and then up ?Bionano is a hyper-technological industry that operates at the level of the human genome. It has developed a platform with an unprecedented ability to detect structural variations in DNA molecules, is active in research for the fight against cancer and other genetic diseases. It presented excellent results days ago and now a category of big investors has started to direct its capital on it , typical feature in this period where many biotech and pharmaceutical companies seem to receive large inflows of capital ( see related ideas ) The advisor Marketmiracle tells us that thanks to the indicator Mmiracle Viewer decomposes the market to identify the positions on the securities of the various investors. It generated an input signal on Bionano Genomics at a price of 7.16 usd with a target of 15.08 usd with a potential profit of 110 %. From the fundamental point of view the company does not shine but it is a characteristic typical of all the companies that operate in the fields in which the investment in search is a necessary and determining part for the own business. I checked the situation in the chart and it seems that the target can actually be reached after a short accumulation phase that could lead the title to the formation of a bullish head shoulders, the high volatility of the stock could then help to reach such an ambitious target. Will Bionano Genomics succeed in its intent ? stay tuned.... This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:BNGOLong
by MarketMiracleAdvisor
2
$ATOS entry PTs 2.30 Target PTs 4.75-5.50-7 and higherPivoting off Support and up-trending towards Resistance, time sequence within Wave analysis Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
NASDAQ:ATOSLong
by BADQOMOCAWGOWLD
No News Pop For CYCNNo news on April 9th and no filings either. But CYCN jumped to $3.10 after-hours. The initial pop began during the final hours of the afternoon session with a big volume spike that pushed the stock back above $3 for the first time, to the upside, in a few weeks. A MELAS Phase 2a study is underway. So the market could be waiting for any updated data to shed light on progress. As it stands right now, top-line data is expected in “mid-2021.” There’s also a Phase 2a study on patients who have Alzheimer’s disease with vascular pathology. The company is expected to initiate this in “mid-2021” as well. Does Friday’s aftermarket momentum have anything to do with its current pipeline? We’ll have to see how Monday begins. In the meantime, CYCN could be one of the penny stocks to watch this week. Quote Source: Best Penny Stocks To Buy Right Now? 3 For This Week’s Watch List
NASDAQ:CYCN
by PennyStocks101
MVMD — Target of shoddy short hit piece by anonymous SA authorThis is a very similar setup to my earlier EXRO call where an anonymous author calling him/herself “Mariner Research Group” put together a shoddy “short thesis” that was quite frankly garbage. It would not surprise me if this “Night Research Group” is the exact same person. Same quality of work, same hastily put together WordPress website with no contact info other than email and no names of who is behind it. Same terrible track record where none of the previous price targets have been reached. Same low follower count. From the technical perspective, MVMD is oversold on the hourly and is approaching oversold territory on the daily chart . .95 gap was filled and support was found at the .96 Fibonacci line. If support holds, it will start forming a bullish Double Bottom pattern. There’s also a gap at 1.10 up above. Decent risk/reward but stop loss is not a bad idea, IMO.
CSE:MVMDLong
by wealth_bakery
$APOP and Quoin Pharmaceuticals Announce Strategic MergerCellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger Cellect shareholders to retain 25% of the combined Company pre-funding Quoin has secured $25 million in committed equity funding from Altium Capital, a highly regarded institutional healthcare investor. Quoin has also negotiated an $18.5 million venture loan from a leading U.S. commercial bank. Completion of the merger is subject to approval of the Cellect and Quoin shareholders and certain other conditions and is expected to close by the end of the second quarter of 2021.
A
by AlenCiken
Why $IMMP soared in December case studyFirst time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo. Statistically significant OS benefit in efti group observed in pre-defined patient groups: +7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age +9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action Collection of OS data ongoing, with final data expected to be reported mid 2021 finance.yahoo.com
NASDAQ:IMMP
by AlenCiken
$PRQR Announces Positive Results from Clinical Trial of QR-421aProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events reported Two pivotal Phase 2/3 trials are expected to start by the end of 2021 finance.yahoo.com
NASDAQ:PRQR
by AlenCiken
$bntc Skyrocket as Morgan Stanley Takes StakeBenitec Shares Skyrocket as Morgan Stanley Takes Stake $BNTC shares blasted higher Tuesday after disclosing in a regulatory filing that Morgan Stanley has a 5.2% stake in the genetic drug company. The stake amounts to 249,174 shares, or about $1.51 million. Benitec‘s “proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration,” the company said. “The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.” www.thestreet.com
NASDAQ:BNTC
by AlenCiken
BNTC Benitech Biopharma we bought the dipMorgan Stanley disclosed in an SEC filing that it had increased its stake in the company by around 5.2%! Don`t worry, it has still upside potential, despite the 130% increase in the Pre-Market. Market Cap of only 15.37M This is a 5X stock, Not trading advice as you know! :) This was a private call from my trading group and one of my top picks for March. You can check the transcripts here: www.patreon.com If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:BNTCLong
by TopgOptions
16
Is This Volume Any Indicator Of A New Trend?MRKR has been a sleeper all year. No major high-volume days and nothing really to write home about. But it managed to pull off a bigger move earlier on. Now that the gap has filled from the drop a few weeks ago & they secured funds, what will this mean for the company's next steps? "An onslaught of Form 4s showed hand fulls of investors and insiders participating in the recent offering. The company raised the money to fund its Phase 2 trial of MT-401 in acute myeloid leukemia. Marker also plans to develop MultiTAA therapies into clinical trials in other indications and conduct manufacturing activities, among other things. In addition to this, analysts have also weighed in recently. Cantor Fitzgerald initiated coverage on Marker this month. The firm started MRKR at Overweight and gave a price target of $6." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MRKR
by PennyStocks101
Back In The Channel AgainMNKD is back in that Fib channel between the .5 and .382 levels. This was a previous channel earlier in the year. Now that the financing deal is done, will it finally see a prolonged uptrend without much interruption? " However, with fresh capital in hand, the company aims at advancing its current pipeline. This includes a Phase 3 clinical trial of its Afrezza inhaled insulin product in pediatric subjects. MannKind also explained that it wants to further the development of product candidates in its pipeline. The company may also use a portion of the proceeds for acquisitions or strategic investments in complementary businesses or technologies. Even with the pullback, analysts seem to remain bullish on the company. SVB Leerink most recently adjusted its price target on the stock. It had previously issued a $3 target but upped it to $5. The firm also carries an Outperform rating on the stock. " Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MNKD
by PennyStocks101